CAR T-Cell therapies in lymphoma: current landscape, ongoing investigations, and future directions

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has significantly improved outcomes for patients with relapsed/refractory large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma, with multiple FDA-approved CAR T products now commercially available. Ongoing studies seek to move CAR T-cells to earlier lines of therapy and to characterize the efficacy and safety of CAR T-cell approaches in additional lymphoma histologies including relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia. Other areas of active research address CAR T in combination with other lymphoma-directed therapies, and mechanisms of CAR T resistance. This review focuses on the FDA-approved anti-CD19 CAR T products for B-cell lymphomas, management of CAR T-cell-associated toxicities, approaches to bridging therapy, and ongoing clinical trials and future research directions across a broad range of lymphoma histologies.

Keywords

CAR T-cells / cell therapy / adoptive immunotherapy / non-Hodgkin lymphoma / aggressive lymphoma / indolent lymphoma / mantle cell lymphoma / diffuse large B-cell lymphoma

References

[1] Siegel RL,Fuchs HE.Cancer Statistics, 2021.CA Cancer J Clin2021;71:7-33

[2] Swerdlow SH,Pileri SA.The 2016 revision of the World Health Organization classification of lymphoid neoplasms.Blood2016;127:2375-90 PMCID:PMC4874220

[3] Crump M,Farooq U.Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.Blood2017;130:1800-8 PMCID:PMC5649550

[4] Epperla N,Cashen AF.Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.Hematol Oncol2017;35:528-35

[5] Jain P,Zhang S.Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.Br J Haematol2018;183:578-87

[6] Martin P,Leonard JP.Postibrutinib outcomes in patients with mantle cell lymphoma.Blood2016;127:1559-63

[7] Casulo C,Dawson KL.Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study.J Clin Oncol2015;33:2516-22 PMCID:PMC4879714

[8] Jain P,Wierda W.Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.Blood2015;125:2062-7 PMCID:PMC4467871

[9] Abramson JS,Gordon LI.Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.Lancet2020;396:839-52

[10] Neelapu SS,Bartlett NL.Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.N Engl J Med2017;377:2531-44 PMCID:PMC5882485

[11] Schuster SJ,Tam CS.JULIET InvestigatorsTisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma.N Engl J Med2019;380:45-56

[12] Wang M,Goy A.KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma.N Engl J Med2020;382:1331-42 PMCID:PMC7731441

[13] Jacobson C,Sehgal AR.Primary analysis of Zuma-5: a phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL).Blood2020;136:40-1

[14] Harding FA,Gross JA,Allison JP.CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones.Nature1992;356:607-9

[15] Savoldo B,Liu E.CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.J Clin Invest2011;121:1822-6 PMCID:PMC3083795

[16] Salter AI,Kennedy JJ.Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.Sci Signal2018;11:1-17 PMCID:PMC6186424

[17] Turtle CJ,Berger C.Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.Sci Transl Med2016;8:1-12 PMCID:PMC5045301

[18] Locke FL,Jacobson CA.Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.Lancet Oncol2019;20:31-42 PMCID:PMC6733402

[19] Ramsborg CG,Weber C.JCAR017 is a defined composition CAR T cell product with product and process controls that deliver precise doses of CD4 and CD8 CAR T cell to patients with NHL.Blood2017;130:4471

[20] Sommermeyer D,Kosasih PL.Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.Leukemia2016;30:492-500 PMCID:PMC4746098

[21] Jacobson CA,Redd R.Axicabtagene Ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity.J Clin Oncol2020;38:3095-106 PMCID:PMC7499617

[22] Jaglowski S,Zhang Y.Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) cellular therapy (CT) registry.Blood2019;134:766

[23] Nastoupil LJ,Feng L.Standard-of-care Axicabtagene Ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium.J Clin Oncol2020;38:3119-28 PMCID:PMC7499611

[24] Pasquini MC,Herrera AF.Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (axi-cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US).Blood2019;134:764

[25] Palomba ML,Siddiqi T.Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in transcend NHL 001.Blood2020;136:10-1

[26] Schuster SJ,Chong EA.Chimeric antigen receptor T cells in refractory B-cell lymphomas.N Engl J Med2017;377:2545-54 PMCID:PMC5788566

[27] Hirayama AV,Hay KA.High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.Blood2019;134:636-40 PMCID:PMC6695558

[28] Hay KA,Li D.Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.Blood2017;130:2295-306 PMCID:PMC5701525

[29] Lee DW,Locke FL.ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.Biol Blood Marrow Transplant2019;25:625-38

[30] Turtle CJ,Berger C.CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.J Clin Invest2016;126:2123-38 PMCID:PMC4887159

[31] Santomasso BD,Salloum D.Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia.Cancer Discov2018;8:958-71 PMCID:PMC6385599

[32] Gust J,Hanafi LA.Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells.Cancer Discov2017;7:1404-19 PMCID:PMC5718945

[33] Nellan A,Cruz Garcia R.Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques.Blood2018;132:662-6 PMCID:PMC6086204

[34] Brudno JN,Shi V.Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease.J Clin Oncol2016;34:1112-21 PMCID:PMC4872017

[35] Oluwole OO,Gisselbrecht C.ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).J Clin Oncol2018;36:TPS7585

[36] Westin J,Flinn I.BELINDA: a phase 3 study evaluating the safety and efficacy of tisagenlecleucel versus standard of care in adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.Clin Lymphoma Myeloma Leuk2019;19:S270-1

[37] Neelapu SS,Ulrickson ML.Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients (Pts) with high-risk large B cell lymphoma (LBCL).Blood2020;136:49

[38] Le Gouill S,Oberic L.Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.Blood2021;137:2307-20

[39] Fowler NH,Dreyling M.Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma: interim analysis of the phase 2 Elara trial.Blood2020;136:1-3

[40] Kochenderfer JN,Kassim SH.Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.J Clin Oncol2015;33:540-9 PMCID:PMC4322257

[41] Porter DL,Frey NV.Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.Sci Transl Med2015;7:303ra139 PMCID:PMC5909068

[42] Turtle CJ,Hanafi LA.Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib.J Clin Oncol2017;35:3010-20 PMCID:PMC5590803

[43] Siddiqi T,Dorritie KA.Updated follow-up of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of transcend CLL 004, including high-risk and ibrutinib-treated patients.Blood2020;136:40-1

[44] Chavez JC,Kharfan-Dabaja MA.CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products.Ther Adv Hematol2019;10:2040620719841581 PMCID:PMC6466472

[45] Jacobsen ED,Oki Y.Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.Blood2015;125:1394-402

[46] Goy A,Ghosh N.Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.Blood2019;134:1024-36 PMCID:PMC6764267

[47] Sehn LH,Flowers CR.Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.J Clin Oncol2020;38:155-65 PMCID:PMC7032881

[48] Salles G,Gonzalez Barca E.Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.Lancet Oncol2020;21:978-88

[49] Frigault MJ,Martinez-Lage M.Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.Blood2019;134:860-6 PMCID:PMC7022436

[50] Novo M,Skrabek PJ.Axicabtagene ciloleucel chimeric antigen receptor T Cell therapy in lymphoma with secondary central nervous system involvement.Mayo Clin Proc2019;94:2361-4

[51] Bennani NN,Nastoupil LJ.Experience with axicabtagene ciloleucel (axi-cel) in patients with secondary CNS involvement: results from the US lymphoma CAR T consortium.Blood2019;134:763

[52] Abbasi A,Shah N.Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.J Hematol Oncol2020;13:1 PMCID:PMC6942268

[53] Siddiqi T,Palmer J.CD19-targeting CAR-T cell therapy in CNS lymphoma.Blood2019;134:4075

[54] Jacobson CA,Miklos DB.Abstract CT055: phase 1/2 primary analysis of ZUMA-6: axicabtagene ciloleucel (Axi-Cel) in combination with atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL).Cancer Res2020;80:CT055

[55] Jaeger U,McGuirk JP.Portia: a phase 1b study evaluating safety and efficacy of tisagenlecleucel and pembrolizumab in patients with relapsed/refractory diffuse large B-CELL lymphoma.Blood2019;134:5325

[56] Ruella M,Shestova O.The Addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma.Clin Cancer Res2016;22:2684-96

[57] Fraietta JA,Patel PR.Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.Blood2016;127:1117-27 PMCID:PMC4778162

[58] Gauthier J,Purushe J.Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.Blood2020;135:1650-60 PMCID:PMC7205814

[59] Wierda WG,Munoz J.Transcend CLL 004: phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).Blood2020;136:39-40

[60] Fraietta JA,Orlando EJ.Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.Nat Med2018;24:563-71 PMCID:PMC6117613

[61] Qasim W,Samarasinghe S.Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells.Sci Transl Med2017;9:eaaj2013

[62] Liu E,Banerjee P.Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors.N Engl J Med2020;382:545-53 PMCID:PMC7101242

[63] Fry TJ,Orentas RJ.CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.Nat Med2018;24:20-8 PMCID:PMC5774642

[64] Koneru M,Spriggs D,Brentjens RJ.IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.Oncoimmunology2015;4:e994446 PMCID:PMC4404840

[65] Avanzi MP,Li X.Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system.Cell Rep2018;23:2130-41 PMCID:PMC5986286

[66] Cherkassky L,Villena-Vargas J.Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.J Clin Invest2016;126:3130-44 PMCID:PMC4966328

[67] Ramos CA,Robertson CS.In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin's lymphomas.Mol Ther2018;26:2727-37 PMCID:PMC6277484

[68] Eyquem J,Giavridis T.Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.Nature2017;543:113-7 PMCID:PMC5558614